BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27998196)

  • 1. Recent trends in neuropathic pain patents.
    Maia RD
    Expert Opin Ther Pat; 2017 May; 27(5):539-546. PubMed ID: 27998196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zucapsaicin for the treatment of neuropathic pain.
    Sałat K; Jakubowska A; Kulig K
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1433-40. PubMed ID: 25171227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium channel blockers for neuropathic pain.
    Zuliani V; Rivara M; Fantini M; Costantino G
    Expert Opin Ther Pat; 2010 Jun; 20(6):755-79. PubMed ID: 20384535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New investigational drugs for the treatment of neuropathic pain.
    Sałat K; Kowalczyk P; Gryzło B; Jakubowska A; Kulig K
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1093-104. PubMed ID: 24896842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.
    Papanas N; Ziegler D
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):393-407. PubMed ID: 27813425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sigma receptor modulators: a patent review.
    Collina S; Gaggeri R; Marra A; Bassi A; Negrinotti S; Negri F; Rossi D
    Expert Opin Ther Pat; 2013 May; 23(5):597-613. PubMed ID: 23387851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological treatment of neuropathic pain].
    Yeng LT
    Drugs Today (Barc); 2009 Oct; 45 Suppl C():7-12. PubMed ID: 20087480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature.
    Kamp J; Van Velzen M; Olofsen E; Boon M; Dahan A; Niesters M
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):1033-1041. PubMed ID: 31693437
    [No Abstract]   [Full Text] [Related]  

  • 9. Research progress of mechanisms and drug therapy for neuropathic pain.
    Yan YY; Li CY; Zhou L; Ao LY; Fang WR; Li YM
    Life Sci; 2017 Dec; 190():68-77. PubMed ID: 28964813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH).
    Pillarisetti S; Khanna I
    Drug Discov Today; 2015 Nov; 20(11):1382-90. PubMed ID: 26259523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical drug therapeutics for neuropathic pain.
    Coderre TJ
    Expert Opin Pharmacother; 2018 Aug; 19(11):1211-1220. PubMed ID: 30044658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic neuropathic pain: mechanisms, drug targets and measurement.
    Finnerup NB; Sindrup SH; Jensen TS
    Fundam Clin Pharmacol; 2007 Apr; 21(2):129-36. PubMed ID: 17391285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials.
    Attal N
    Continuum (Minneap Minn); 2012 Feb; 18(1):161-75. PubMed ID: 22810075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for neuropathic pain.
    Gilron I; Dickenson AH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):329-41. PubMed ID: 24793304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and molecular mechanisms driving neuropathic pain: recent advancements and challenges.
    Fernandes V; Sharma D; Vaidya S; P A S; Guan Y; Kalia K; Tiwari V
    Expert Opin Ther Targets; 2018 Feb; 22(2):131-142. PubMed ID: 29285962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.
    Dohi T; Morita K; Kitayama T; Motoyama N; Morioka N
    Pharmacol Ther; 2009 Jul; 123(1):54-79. PubMed ID: 19393690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathic pain in children.
    Howard RF; Wiener S; Walker SM
    Arch Dis Child; 2014 Jan; 99(1):84-9. PubMed ID: 24114955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation.
    Intiso D; Basciani M; Santamato A; Intiso M; Di Rienzo F
    Toxins (Basel); 2015 Jun; 7(7):2454-80. PubMed ID: 26134256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sigma-1 receptors and animal studies centered on pain and analgesia.
    Davis MP
    Expert Opin Drug Discov; 2015; 10(8):885-900. PubMed ID: 26037105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of peripheral neuropathic pain.
    Stacey BR
    Am J Phys Med Rehabil; 2005 Mar; 84(3 Suppl):S4-16. PubMed ID: 15722782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.